Noting with appreciation the work done by the Technology and Economic Assessment Panel and its Medical Technical Options Committee,

Noting with appreciation the progress made since the adoption of decision XV/5 by Parties not operating under paragraph 1 of Article 5 of the Montreal Protocol in establishing a certain date by which they will cease submitting nominations for metered-dose inhalers where the sole active ingredient is salbutamol,

Recalling paragraph 6 of decision XV/5 relating to the phase-out of chlorofluorocarbons for metered-dose inhalers where the active ingredient is not solely salbutamol,

1. To authorize the levels of production and consumption for 2006 and 2007 necessary to satisfy essential uses of chlorofluorocarbons for metered-dose inhalers for asthma and chronic obstructive pulmonary disease as specified in the annex to the present decision;
2. That Parties not operating under paragraph 1 of Article 5 of the Montreal Protocol, when licensing, authorizing, or allocating essential-use exemptions for chlorofluorocarbons for a manufacturer, shall take into account pre- and post-1996 stocks of controlled substances as described in paragraph 1 (b) of decision IV/25, such that no more than a one‑year operational supply is maintained by that manufacturer;
3. With reference to paragraph 6 of decision XV/5, to request that Parties not operating under paragraph 1 of Article 5 of the Montreal Protocol submit a date to the Ozone Secretariat prior to the Eighteenth Meeting of the Parties by which time a regulation or regulations to determine the non‑essentiality of the vast majority of chlorofluorocarbons for metered-dose inhalers where the active ingredient is not solely salbutamol will have been proposed;

Annex

Essential-use nominations for 2006 and 2007 of chlorofluorocarbons for metered-dose inhalers approved by the Seventeenth Meeting of the Parties (metric tonnes)